OptimizeRx Corp.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a OPRX research report →
Range $11 – $12
Price Chart
About the company
OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support.
- CEO
- Stephen L. Silvestro
- IPO
- 2007
- Employees
- 133
- HQ
- Waltham, MA, US
Get TickerSpark's AI analysis on OPRX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $126.68M
- P/E
- 26.59
- Fwd P/E
- 8.01
- PEG
- 0.00
- P/S
- 1.41
- P/B
- 0.99
- EV/EBITDA
- 7.58
- Div Yield
- 0.00%
- Gross Margin
- 74.20%
- Op Margin
- 12.65%
- Net Margin
- 5.33%
- ROE
- 3.84%
- ROIC
- 4.71%
Latest fiscal year · YoY change
- Revenue
- $109.43M+18.8%
- Gross Profit
- $69.27M+16.7%
- Op Income
- $12.06M
- Net Income
- $5.13M+125.5%
- EPS
- $0.28+125.5%
- OCF Growth
- +282.8%
- FCF Growth
- +290.6%
- 52W High
- $15.59
- 52W Low
- $4.54
- 50D MA
- $8.38
- 200D MA
- $7.07
- Beta
- 1.15
- RSI (14)
- 34
- Avg Volume
- 190.65K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
OptimizeRx beat Q3 expectations on revenue and EBITDA, but lowered full-year revenue guidance because fourth-quarter conversion is lagging despite stronger 2027 signals.· November 11, 2026
- Q3 revenue was $21.6 million and adjusted EBITDA was $6.3 million, both above consensus.
- Revenue declined 17% year over year, but adjusted EBITDA rose from $5.1 million to $6.3 million and margin improved to about 29%.
- Full-year 2026 revenue guidance was cut to $87 million to $93 million, while adjusted EBITDA guidance stayed at $21 million to $25 million.
- Management said contracted revenue remains about 20% below prior year and fourth-quarter visibility is limited, creating execution risk.
- The company highlighted early traction from programmatic DSP partnerships and a previously lost top customer starting to spend again in Q4.
Third-quarter 2026 revenue was $21.6 million, down 17% from $26.1 million in the prior-year quarter. Net income was $1.2 million, or $0.06 per diluted share, versus $0.8 million, or $0.04 per share, last year; non-GAAP net income was $3.8 million, or $0.20 per diluted share, versus $3.1 million, or $0.16 per diluted share. Adjusted EBITDA was $6.3 million versus $5.1 million last year, with adjusted EBITDA margin at about 29%, up more than 900 basis points year over year. Full-year 2026 guidance was updated to revenue of $87 million to $93 million and adjusted EBITDA of $21 million to $25 million; management also said gross margin is expected in the low 70% range for full-year 2026.
Stephen L. Silvestro framed the quarter as proof that OptimizeRx’s business model is becoming more profitable and scalable, citing margin strength, cost discipline, and the completion of a cost reduction initiative in the first half. He emphasized that the revenue guide cut was about timing and conversion of customer spend, not a change in the long-term opportunity, and said the company is seeing encouraging signs for 2027, including pent-up demand and renewed spending from a previously displaced top customer. His tone was confident but careful, repeatedly stressing transparency and the need to avoid overpromising on Q4.
Edward Stelmakh focused on the financial improvement: revenue fell 17%, but expenses dropped $5.1 million year over year to $18.9 million, helped by lower cost of revenue and compensation expense, despite $700,000 of severance costs. He said operating cash flow was $12.9 million for the first nine months of 2026, cash on hand was $22.3 million, and debt was reduced to $13.4 million at quarter end and then to $10.4 million after an additional $3 million paydown post-quarter. He reiterated that gross margin should land in the low 70% range for 2026 and said the company remains committed to paying down debt ahead of schedule while also executing on share repurchases.
Analysts focused on three issues: how far the new programmatic DSP partnerships can reach, whether Q3’s weak NRR of 83% was the trough, and how much of Q4 is already contracted. Management said the three DSPs likely cover about 60% to 70% of the programmatic space and early results are encouraging, but commercialization is still early. On NRR, they suggested the 83% level may be the trough and said it should improve as the large disrupted client normalizes in 2027. They also said full-year midpoint guidance is a little over 90% contracted, versus the mid-90% range in prior years, leaving some Q4 work to do.
The bull case from this call is that OptimizeRx is showing strong operating leverage: revenue fell, but EBITDA and margins improved sharply, and management expects gross margin to stay in the low 70% range. Management also pointed to early 2027 strength, renewed customer spending, expanding mid-tier and long-tail demand, and growing distribution through DeepIntent, Trade Desk, and PulsePoint.
The main bear case is that near-term revenue execution is still weak: contracted revenue is about 20% below prior year, Q4 visibility is limited, and management lowered full-year revenue guidance. NRR fell to 83% because of reduced spend from a large customer, and management said much of the apparent improvement depends on customers converting budgets in a short window before year-end.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 76.9%
- Shares Outstanding
- 18.91M
- Float Shares
- 14.53M
of shares held by institutions
117 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Whetstone Capital Advisors, LLC | 1.51M | 0 |
| Royce & Associates LP | 1.32M | ▲ 225.66K |
| Kennedy Capital Management LLC | 1.21M | ▲ 564.41K |
| Vanguard Group Inc | 1.14M | ▲ 77.82K |
| Vanguard Capital Management LLC | 699.60K | 0 |
| Blair William & Co/Il | 615.20K | ▲ 7.27K |
| Rice Hall James & Associates, LLC | 608.71K | ▼ 25.13K |
| Mink Brook Asset Management LLC | 500.48K | ▲ 359.25K |
| Marshall Wace, Llp | 459.36K | ▲ 297.18K |
| Dimensional Fund Advisors LP | 443.02K | ▼ 34.67K |
| Blackrock, Inc. | 431.01K | ▼ 14.37K |
| Parkman Healthcare Partners LLC | 381.35K | ▲ 31.01K |
Held by 66 ETFs
Biggest fund positions in OPRX by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 1, 26 | D'Silva Andrew J. | other | 414 |
| Sep 1, 26 | D'Silva Andrew J. | other | 1,432 |
| Aug 20, 26 | Silvestro Stephen L | other | 79,200 |
| Aug 20, 26 | D'Silva Andrew J. | other | 57,600 |
| Aug 20, 26 | Merrell Brendan W. | other | 57,600 |
| Aug 20, 26 | Odence-Ford Marion | other | 57,600 |
| Aug 21, 26 | Merrell Brendan W. | other | 1,020 |
| Aug 21, 26 | Silvestro Stephen L | other | 1,737 |
| Aug 21, 26 | Odence-Ford Marion | other | 1,529 |
| Aug 21, 26 | D'Silva Andrew J. | other | 1,243 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our OPRX coverage
Recent articles, reports, and earnings notes.
No research on OPRX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate OPRX report →Head-To-Head Survey: OptimizeRx (NASDAQ:OPRX) vs. CareCloud (NASDAQ:CCLD)
defenseworld.net · Nov 19
OptimizeRx to Participate in the 15th Annual ROTH Technology Conference
globenewswire.com · Nov 16
These Analysts Cut Their Forecasts On OptimizeRx After Q3 Results
benzinga.com · Nov 12
OptimizeRx Corporation (OPRX) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 11
What OptimizeRx (OPRX) Said on Its Q3 Earnings Call
marketbeat.com · Nov 11
OptimizeRx Corp. (OPRX) Q3 Earnings and Revenues Beat Estimates
zacks.com · Nov 11
OptimizeRx Reports Third Quarter 2026 Financial Results and Updates Fiscal Year 2026 Guidance
globenewswire.com · Nov 11
OptimizeRx Sets Third Quarter 2026 Conference Call for November 11, 2026 at 4:30 p.m. ET
globenewswire.com · Oct 28
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.